Pegvisomant

Identification

Name
Pegvisomant
Accession Number
DB00082 / N824AOU5XV
Groups
Somavert
Description

Pegvisomant is a rather selective boom hormone (GH) receptor antagonist. it's miles used to deal with acromegaly. in contrast to dopamine or somatostatin analogs (which inhibit increase hormone secretion), this drug absolutely blocks the hepatic (GH-mediated) manufacturing of insulin like increase aspect (IGF-1), that is the primary mediator of boom hormone activity.

Pharmacology

Pharmacodynamics

Somavert is used for the treatment of acromegaly, which arises from excessive IGF-1 levels. Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased serum concentrations of insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3). This reduces the symptoms of acromegaly.

Indication

Pegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.

Action

Somavert selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH. This leads to the normalization of serum IGF-1 levels.